Papers
1
Total Citations
13
H-Index
1
About
Dr. Marc Mauermann is a leading figure in bioprocess engineering, specializing in the translation of advanced therapy medicinal products (ATMPs) from laboratory research to commercial-scale manufacturing. His primary research focuses on the critical challenge of automating and scaling up the production of tissue-engineered products (TEPs) and cell-based therapies, bridging the notorious "valley of death" between clinical trials and market access. His most cited work, "From Single Batch to Mass Production–Automated Platform Design Concept for a Phase II Clinical Trial Tissue Engineered Cartilage Product" (2021, 13 citations), provides a seminal blueprint for industrializing complex biological manufacturing processes. This paper directly addresses the unmet clinical needs for progressive and chronic diseases by proposing a closed, automated platform that ensures product consistency, quality, and cost-effectiveness. Dr. Mauermann’s contributions are pivotal for the ATMP field, offering a practical roadmap to transform promising regenerative therapies into accessible, mass-produced treatments. His work is essential reading for students and researchers aiming to navigate the engineering and regulatory hurdles of bringing life-saving cell and tissue therapies to patients worldwide.
Research Focus
Key Achievements
Top Papers
- 1